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Introduction {#sec1}
============

An array of mutations (e.g., non-sense, frameshift, missense) in the gene encoding proline-rich transmembrane protein 2 (PRRT2) are linked to a wide group of paroxysmal disorders, including paroxysmal kinesigenic dyskinesia (PKD), benign familial infantile seizures, infantile convulsions with choreoathetosis, and episodic ataxia ([@bib8]). To date, more than 1,500 individuals with 70 different *PRRT2* mutations have been reported ([@bib7]). However, 78% of patients described so far carry the same frameshift insertion (c.649dupC), which leads to a premature stop codon and non-sense-mediated decay ([@bib4], [@bib8], [@bib45]). Biallelic (homozygous and compound heterozygous) mutations in *PRRT2* have also been reported in a small number of PKD patients, typically associated with a more severe movement disorder phenotype, learning difficulties, and only partial response to carbamazepine ([@bib5], [@bib8]). Furthermore, PRRT2 knockout (KO) and loss-of-function mutant mice display pleiotropic paroxysmal phenotypes and faithfully recapitulate the neurological diseases associated with *PRRT2* mutations ([@bib26], [@bib39]). These results indicate that pathogenicity of *PRRT2* mutations is likely due to loss of function and a dominant-negative effect.

PRRT2 is a neuron-specific protein, associating mostly with the pre-synaptic area and to a much lower extent in post-synaptic densities ([@bib42], [@bib43]). Acute silencing of PRRT2 during neuronal development causes a decrease in the density of synaptic connections as well as impairments in synaptic transmission ([@bib42]). This hints at a potential role of PRRT2 in maintaining the pre-synaptic structure and function. Furthermore, screening of PRRT2 interactors by complementary methodologies ([@bib18], [@bib36], [@bib39], [@bib42]) reveals that PRRT2 binds to the components of synaptic fusion machinery, particularly the SNARE (soluble N-ethylmaleimide-sensitive factor attachment protein receptor) proteins ([@bib18], [@bib36]) and the Ca^2+^ sensors synaptotagmin 1/2 ([@bib42]). This suggests that PRRT2 is likely involved in regulating synaptic vesicle fusion and the ensuing release of neurotransmitters ([@bib42], [@bib43]). However, the complex nature of the cellular environment, compounded by the variable phenotypes and the pleiotropic effects of genetic manipulations, preclude further insight into the molecular mechanisms. Thus, a reductionist approach, in which variability of some of the parameters is restricted, is required to deduce the physiological role of PRRT2 and the underlying molecular mechanisms.

Fusion of synaptic vesicles is mediated by the neuronal SNARE proteins wherein polarized assembly of the vesicle-associated v-SNARE (VAMP2) with its cognate t-SNARE (syntaxin1a/SNAP25) on the target membranes provides the energy to fuse the bilayers and open the fusion pore ([@bib10], [@bib35], [@bib46]). This constitutive process is tightly controlled by several regulatory elements to achieve Ca^2+^-synchronized rapid neurotransmitter release ([@bib37], [@bib38]). Reconstituted *in vitro* fusion assays, typically monitoring lipid mixing between compartments, are an important tool in the study of the membrane fusion process ([@bib10], [@bib16], [@bib46]). This versatile assay, wherein the relevant proteins and co-factors can be added or altered individually, has greatly contributed to our understanding of synaptic fusion ([@bib10], [@bib16], [@bib46]) and the mechanistic details of synaptic fusion regulators, including synaptotagmin1, complexin, Munc18, and Munc13 ([@bib6], [@bib17], [@bib22], [@bib24], [@bib33]).

We use this reconstituted setup, at both bulk and single-vesicle levels, to establish the functional capabilities of PRRT2 and to obtain a detailed understanding of the structure-function relationship. We report that the N-terminal proline-rich region on PRRT2 selectively blocks synaptic SNARE-mediated fusion by preventing the initial engagement of the SNARE proteins and thus modulates the vesicle priming process. Fluorescence imaging analysis of neuroexocytosis in PC12 cells confirms that this function extends to regulated exocytosis. Remarkably, some PKD-associated PRRT2 mutations disrupt the SNARE-modulatory function, revealing a possible mechanism that might underlie the associated paroxysmal phenotype.

Results {#sec2}
=======

PRRT2 Inhibits Synaptic SNARE-Mediated Fusion of Liposomes {#sec2.1}
----------------------------------------------------------

Informed by the recent findings that PRRT2 may interact with the core synaptic fusion machinery ([@bib18], [@bib39], [@bib42]), we used a defined fusion system ([@bib46]) to identify the molecular role of PRRT2 at the synapse. To this end, we purified the full-length PRRT2 as a GST-tagged protein using a bacterial expression system. The purity of the isolated PRRT2 protein was checked using Coomassie-stained SDS-PAGE analysis ([Figure 1](#fig1){ref-type="fig"}A), and the identity was verified using an anti-PRRT2 immunoblot ([Figure 1](#fig1){ref-type="fig"}B). Both showed a single band at ∼60 kDa, comparable with the native PRRT2 protein in the brain synaptosomal (P2) fraction ([Figures 1](#fig1){ref-type="fig"}A and 1B). Subsequently, we examined if there is a direct molecular interaction between purified PRRT2 and the SNARE proteins. His^6^ pull-down assays revealed a weak but comparable binding of purified PRRT2 with both the VAMP2 and the t-SNARE complexes ([Figure S1](#mmc1){ref-type="supplementary-material"}A). We used microscale thermophoresis to quantify this interaction. Titration of the t-SNARE or the assembled SNARE complex in solution exhibited a dose-response curve, but binding was not saturated even at the highest concentrations tested (∼150 μM for t-SNARE and ∼60 μM for the SNARE complex) ([Figures S1](#mmc1){ref-type="supplementary-material"}B and S1C). So, PRRT2 interacts directly with individual SNARE proteins and the SNARE complex but has a low affinity (K~d~ ≥ 50 μM) under soluble conditionsFigure 1PRRT2 Inhibits Synaptic SNARE-Mediated Fusion under Reconstituted Conditions(A) Purity of the recombinant PRRT2 purified using bacterial expression setup is confirmed using Coomassie-stained SDS-PAGE analysis.(B) Identity of the purified protein is verified using western blot analysis with a PRRT2 antibody. The native protein from the P2 synaptosomal fraction was used as positive control.(C) Purified PRRT2 reconstituted into VAMP2- or t-SNARE-containing liposomes using detergent dilution and dialysis method is analyzed using Coomassie-stained SDS-PAGE analysis.(D) Cryoelectron microscopy analysis of reconstituted t-liposomes shows that PRRT2 incorporation does not alter the size or other physical attributes of the liposomes. Representative micrographs of t-SNARE liposomes with or without PRRT2 (1:1) incorporated are shown.(E) PRRT2 introduced in either the v- or t-liposomes inhibited synaptic SNARE-mediated fusion of liposomes monitored by NBD dequenching assay. Negative control with soluble cytoplasmic domain of VAMP2 (CDV) added in excess to titrate out the t-SNAREs shows that PRRT2 is not inherently fusogenic. Representative fusion curves are shown.(F) PRRT2 displays a typical dose-response curve corresponding to a unique bio-molecular interaction. The dose-response curve was constructed from the maximal fusion levels observed for varying PRRT2 concentrations. Dotted line shows a single exponential decay fit, which estimates the half-maximal response at a 1:1 PRRT2/t-SNARE ratio. Average values and SDs from a minimum of three independent experiments are shown.(G) Schematic of the single-vesicle fusion analysis. Fluorescent-labeled lipid (ATTO647-PE) included in v-SNARE-containing liposomes (v-SUV) enables us to track the association and fusion of single vesicles with the free-standing planar bilayer using confocal microscopy. Typically, the vesicle appears in the field of view when it loosely tethers to the bilayer (left), progresses to firmly dock concomitant with an increase in the fluorescence signal (middle), and then proceeds to fuse (right), evidenced by the radial diffusion of the fluorescent lipids in the bilayer after transfer due to membrane fusion. Our automated software enables the tracking of individual vesicles and classify the different stages, leading to fusion.(H) PRRT2 reduces the fraction of vesicles that proceed to fuse in the single-vesicle analysis. In the absence of PRRT2, ∼60% of all observed vesicles proceed to full fusion. PRRT2 introduced in the v-SUVs significantly reduces (∼50%) the fraction of fused vesicles. Average values and SDs from a minimum of three independent experiments are shown.

To assess the functional relevancy of this interaction, we used the reconstituted, lipid-mixing assay based on NBD (N-\[7-nitro-2-1,3-benzoxadiazol-4-yl\])-RHO (lissamine rhodamine B) energy transfer ([@bib10], [@bib46]) and as such incorporated the purified PRRT2 into SNARE-containing liposomes at a defined PRRT2/SNARE ratio ([Figure 1](#fig1){ref-type="fig"}C). Cryoelectron microscopy, applied as a quality control of the proteoliposome reconstitution, showed that the majority of vesicles in both the control and PRRT2-containing samples were unilamellar, with diameters of 70−100 nm and no structural abnormalities ([Figure 1](#fig1){ref-type="fig"}D).

The synaptic SNAREs were reconstituted at physiologically relevant surface densities, and because PRRT2 localizes primarily to the pre-synaptic plasma membrane, it was first introduced into t-SNARE liposomes at the same density (∼50 copies of each protein per vesicle). As shown in [Figure 1](#fig1){ref-type="fig"}E, PRRT2 lowered both the rate and the extent of SNARE-mediated fusion and reduced the total fusion after 2 hr by ∼50%. This was a dynamic effect and did not require pre-binding to the SNAREs, as we observed similar inhibition of fusion (∼54%) with PRRT2, at the same density as before, incorporated into v-SNARE liposomes ([Figure 1](#fig1){ref-type="fig"}E). We also tested and confirmed that PRRT2 blocks full fusion with a content release assay ([@bib1], [@bib34]) using calcium-loaded t-vesicles fusing with v-nanodiscs and a calcium-sensitive fluorophore, Mag-Fluo-4, included in the external medium ([Figure S1](#mmc1){ref-type="supplementary-material"}D). Furthermore, we analyzed fusion by systematically varying the PRRT2/t-SNARE ratio. Consistent with defined molecular interaction, PRRT2 inhibited fusion in a concentration-dependent manner and exhibited a classical dose-response curve, with half-maximal response corresponding to about one copy of PRRT2 for each t-SNARE and near complete block of fusion at two or three copies of PRRT2 per t-SNARE ([Figures 1](#fig1){ref-type="fig"}F and [S1](#mmc1){ref-type="supplementary-material"}E). In all cases, control experiments confirmed that PRRT2 is not inherently fusogenic and the cognate SNAREs are required to catalyze fusion under all conditions.

To dissect this further, we analyzed the effect of PRRT2 on rapid fusion of single vesicles containing VAMP2 (v-liposome) with planar, free-standing bilayers containing the synaptic t-SNAREs (S.K.R., A. Gohlke, F. Li, J.C., X. Wu, J.E.R., and F. Pincet, unpublished data). At low vesicle concentration, the fluorescent marker (Atto 647 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine \[ATTO647-DOPE\]) included into the v-liposome allows us to readily observe and quantitate individual vesicles attaching and then fusing with the planar bilayer using standard confocal microscopy ([Figure 1](#fig1){ref-type="fig"}G). With the SNAREs alone, ∼60% of the vesicles that attach proceeded to fuse, while the remainder (∼40%) stayed attached and gradually photobleached or visibly dissociated from the bilayer ([Figure 1](#fig1){ref-type="fig"}H). Inclusion of PRRT2 in the v-liposomes significantly reduced the proportion of fusion events, wherein only a minor fraction (∼30%) of attached vesicles progressed to fuse ([Figure 1](#fig1){ref-type="fig"}H). Noteworthy, the magnitude of fusion inhibition (∼50%) in this analysis is comparable with that observed in the bulk fusion assays ([Figures 1](#fig1){ref-type="fig"}E and 1F). Taken together, our data indicate that PRRT2 directly binds synaptic SNARE protein to negatively regulate the SNARE-mediated vesicle fusion process.

PRRT2 Blocks Synaptotagmin1/Ca^2+^-Regulated Fusion of Liposomes {#sec2.2}
----------------------------------------------------------------

At the synapse, SNARE-catalyzed vesicle fusion is chaperoned by several regulatory elements that confer speed and synchronicity ([@bib37], [@bib38]). A key regulator is the Ca^2+^ sensor synaptotagmin1 (Syt1), which couples vesicle fusion to Ca^2+^ influx following action potential ([@bib2], [@bib9]). In fact, PRRT2 has been predicted to bind Syt1 on the basis of co-immunoprecipitation studies ([@bib42]), and our MST analysis confirmed this, revealing a direct but weak interaction, comparable to the SNARE proteins ([Figure S1](#mmc1){ref-type="supplementary-material"}F). So, we examined if PRRT2 modulates the Syt1-regulated membrane fusion. In a functional reconstitution with full-length Syt1 incorporated into the v-liposomes, PRRT2 (included at a 1:1 ratio to the t-SNAREs) inhibited both the Ca^2+^-independent and Ca^2+^-triggered membrane fusion ([Figure 2](#fig2){ref-type="fig"}A) and, remarkably, to same extent when Syt1/Ca^2+^ were absent ([Figures 2](#fig2){ref-type="fig"}B and [S2](#mmc1){ref-type="supplementary-material"}A). This indicates that the PRRT2 clamping function is realized even under conditions of regulated exocytosis. It further reveals that PRRT2 exerts an irreversible block on fusion, unlike other synaptic regulators such as complexin ([@bib24]), and does so by selectively acting on the SNARE proteins, independent of other co-factors.Figure 2PRRT2 Blocks Ca^2+^-Regulated Exocytosis under Both Reconstituted and Physiological Conditions(A) Reconstituted fusion assay with synaptotagmin in the v-SNARE vesicles shows that PRRT2 also blocks synaptotagmin-regulated fusion, and the block is not altered by addition of Ca^2+^. Representative fusion curves are shown.(B) Direct comparison of the PRRT2 fusion block under both synaptotagmin-free and synaptotagmin ± Ca^2+^ conditions shows the extent of inhibition (one copy of PRRT2 per t-SNARE) is comparable under all conditions tested, suggesting that SNARE proteins are the primary target for PRRT2. Average values and SDs from three or four independent experiments are shown.(C) Western blot analysis shows the PC12 cells lack endogenous PRRT2, thus providing a virgin environment to test the functional capabilities of PRRT2 under physiologically relevant conditions.(D) TIRF microscopy setup used to observe single exocytotic events in PC12 cells transfected with VAMP2-pHluorin (±PRRT2), stimulated by local perfusion of KCl supplemented with 2.5 mM Ca^2+^. Live cell imaging analysis using TIRF microscopy shows that PRRT2 inhibits evoked fusion. It blocks both partial and full-fusion events, as characterized by their distinctive fluorescence signatures ([Figure S2](#mmc1){ref-type="supplementary-material"}B). Average values and SDs from three or four independent experiments, with a minimum of 50 cells under each conditions, are shown. Statistical significance was established using a Wilcoxon-Mann-Whitney test to account for the non-normal distribution of the data.

PRRT2 Blocks Ca^2+^-Regulated Neuroexocytosis in PC12 Cells {#sec2.3}
-----------------------------------------------------------

To physiologically validate these findings, we examined the effect of PRRT2 on Ca^2+^-evoked exocytosis in rat adrenal pheochromocytoma (PC12) cells. PC12 cells are widely used as a model for neurosecretion because regulated exocytosis in the PC12 cells is mediated by the neuronal fusion machinery ([@bib3], [@bib47]). In addition, the PC12 cell line lacks endogenous PRRT2 and thus provides an ideal background to establish the functional capabilities of PRRT2 in a cellular context ([Figure 2](#fig2){ref-type="fig"}C). We used live-cell fluorescence imaging to monitor single exocytotic events by using pHluorin-tagged (luminal) VAMP2 ([Figure 2](#fig2){ref-type="fig"}D). We chose VAMP2-pHluorin because it serves as a universal marker for all vesicle types (small clear vesicles, small and large dense core vesicles) in PC12 cells. In our total internal reflection fluorescence (TIRF) microscopy setup ([@bib27], [@bib31], [@bib40]), the pHluorin signal increase upon fusion is automatically detected by a differential analysis of the images and fitted to a Gaussian to classify into full-fusion or partial-fusion events on the basis of its duration and decay characteristics ([@bib32], [@bib40], [@bib49]) ([Figure S2](#mmc1){ref-type="supplementary-material"}B). Expression of PRRT2 in PC12 cells strongly reduced the number of fusion events triggered by potassium chloride (KCl) depolarization in the presence of Ca^2+^ ([Figure 2](#fig2){ref-type="fig"}D). Detailed analysis further revealed that PRRT2 inhibits both the full- and partial-fusion events, without altering the ratio between the two modes of fusion ([Figure 2](#fig2){ref-type="fig"}D). Thus, PRRT2 plays a vital role in moderating synaptic SNARE-mediated vesicle fusion in the cellular context.

PRRT2 Modulates the Vesicle Priming Process {#sec2.4}
-------------------------------------------

Vesicular exocytosis involves a series of morphologically and molecularly defined sequential steps wherein vesicles first translocate to and are loosely "tethered" at the plasma membrane (PM), then undergo preparatory molecular reactions termed "priming/docking," which render them fusion-competent and culminate in membrane fusion, either constitutively or when triggered by an external stimulus ([@bib44]). So, we looked into which stage(s) of this sequential process is regulated by PRRT2.

Ammonium chloride (NH~4~Cl) treatment, which neutralizes the pH and permits visualization of all tethered/docked but unfused vesicles by TIRF microscopy, showed that PRRT2 does not substantially alter the number of vesicles that are at or near (∼250 nm) the PM ([Figure 3](#fig3){ref-type="fig"}A). This was corroborated by electron microscopy (EM) analysis, which showed that PPRT2 expression had only a modest effect on the density and distribution of the trafficking dense core vesicles ([Figure 3](#fig3){ref-type="fig"}B). The minor difference (∼10% reduction) in the number of vesicles locating close to the PM ([Figures 3](#fig3){ref-type="fig"}A and 3B) cannot explain the robust inhibition of exocytosis by PRRT2 ([Figure 2](#fig2){ref-type="fig"}D). However, the EM/TIRF analysis does not have resolution to distinguish between loosely tethered and primed/docked vesicles in the cellular context, so we used a reconstituted setup to investigate in detail.Figure 3PRRT2 Impedes SNARE-Dependent Docking/Priming of Vesicles(A) Tethering/docking of the vesicles surveyed by neutralizing the pH in all vesicles with 50 mM ammonium chloride under TIRF conditions shows that PRRT2 expression does not substantially alter the number of vesicles at or near the PM. Average values and SDs from three independent experiments with a minimum of 25 cells per condition are shown.(B) EM analysis of serial sections of PC12 cells with (left bottom) and without (left top) PRRT2 expression confirms that PRRT2 does not alter the density and distribution of the dense core vesicles. The proportional distribution of the dense core vesicles (dark spots) from the PM is shown. The average distribution from three independent experiments (∼25 cells in total) is shown.(C) TIRF microscopy-based analysis reveals that PRRT2 inhibits the docking of individual v-SNARE liposomes to a t-SNARE-containing planar supported bilayer. To get an accurate estimate of the docked vesicles, VAMP2 protein with mutations in the C-terminal half (L70D, A74R, A81D, and L84D, termed VAMP2-4X) that eliminates fusion activity was used, and the number of firmly docked vesicles was estimated after a 10 min incubation followed by an extensive buffer wash. The number of docked vesicles normalized to the PRRT2-free condition from three to five independent experiments is shown. The error bars indicate the SEM.(D and E) PRRT2 has a moderate effect on the membrane fusion process. (D) The single-vesicle fusion analysis showing that PRRT2 does not change the efficiency of the fusion process as the percentage of firmly docked vesicles that ultimately fuse is unaltered by the inclusion of PRRT2. However, PRRT2 introduces a slight delay in the fusion of the docked vesicles. The percentage survival curve of docked vesicles (E) reveals that the vesicles containing PRRT2 on an average take longer to fuse compared with control vesicles. Average and SEM from five independent single-vesicle fusion analyses are shown.

We used a TIRF microscopy-based assay to examine the effect of PRRT2 on SNARE-mediated docking/priming of vesicles ([@bib11], [@bib50]). To assay for single-vesicle docking, freely diffusing fluorescently (ATTO647-DOPE) labeled v-SNARE liposomes were allowed to react with a t-SNARE-containing planar supported bilayer for 10 min and imaged following an extensive wash to remove any non-specifically bound vesicles. To get an accurate estimate of the docked vesicles, we used VAMP2 protein with mutations in the C-terminal half (L70D, A74R, A81D, and L84D, termed VAMP2-4X) that eliminates fusion activity without impeding the docking process ([@bib13], [@bib14]). A control experiment with protein-free liposomes confirmed that the docking of vesicle under these conditions is strictly dependent on the SNARE protein, and PRRT2 introduced in the v-liposomes greatly reduced (∼60%) the number of bound vesicles ([Figures 3](#fig3){ref-type="fig"}C and [S3](#mmc1){ref-type="supplementary-material"}). In fact, this impediment in docking could account for the inhibition observed in the single-vesicle analysis ([Figure 1](#fig1){ref-type="fig"}H).

Consequently, we assessed PRRT2's role in regulating membrane fusion itself. Using our single-vesicle fusion system ([Figure 1](#fig1){ref-type="fig"}G), we found that PRRT2 does not alter the fusion efficiency ([Figure 3](#fig3){ref-type="fig"}D) as the fraction of firmly docked vesicle that end up fusing was comparable in the presence and absence of PRRT2 (76% and 84%, respectively). However, PRRT2 slightly slowed down the overall fusion process ([Figure 3](#fig3){ref-type="fig"}E). This is apparent in the survival analysis (i.e., fraction of the unfused vesicles as a function of time), wherein the majority of docked vesicles fuse within 1--2 s in the absence of PRRT2 but in its presence stay docked longer, with the majority fusing around 3--4 s ([Figure 3](#fig3){ref-type="fig"}E). This slight delay in fusion is likely due to an impediment imposed by PRRT2 on the assembly of the critical number of SNARE complexes required to drive membrane fusion. Thus, our data clearly demonstrate that PRRT2 acts primarily to moderate the priming process, resulting in a reduction of the number of fusion-competent vesicles and has a modest effect on the fusion of pre-docked vesicles.

The Proline-Rich N-Terminal Domain of PRRT2 Impedes SNARE Engagement {#sec2.5}
--------------------------------------------------------------------

SNARE proteins assemble in a polarized fashion, consisting of two sequential steps ([@bib19], [@bib21]). The first step is the N-terminal assembly, in which the SNAREs zipper approximately two-thirds of the way to completion. This step docks the vesicle to the PM and induces a structural optimization in the SNAREs required for fusion ([@bib19], [@bib20], [@bib21]). The second step is the assembly of the C-terminal end of the SNAREs, which brings the membranes closer and provides energy for fusion ([@bib19], [@bib20], [@bib25]). We used a fluorescence resonance energy transfer (FRET) assay, with fluorescent probes introduced along the SNARE proteins, to directly track PRRT2's effect on complex assembly ([@bib14]). As shown in [Figure 4](#fig4){ref-type="fig"}A, PRRT2 lowers the FRET signal between Oregon green and Texas red probes introduced at the N termini of SNAP25 and VAMP2, respectively, in a concentration-dependent manner. We obtained indistinguishable results from FRET probes introduced at the C termini ([Figure 4](#fig4){ref-type="fig"}B), implying that PRRT2 essentially impedes the initial engagement of the SNARE proteins. Inclusion of Syt1, with or without Ca^2+^, had no effect on the PRRT2 inhibition of SNARE N-terminal assembly ([Figures S4](#mmc1){ref-type="supplementary-material"}A and S4B), further signifying that SNAREs are the primary targets of PRRT2.Figure 4The N-Terminal Proline-Rich Domain of PRRT2 Blocks SNARE Complex Assembly(A) Assembly of the SNARE complex followed using FRET between Oregon green-labeled t-SNARE and Texas red-labeled VAMP2 introduced in the N terminus (SNAP25 residue 20 and VAMP2 residue 28) shows that PRRT2 blocks the initial engagement of the SNARE complex and does so in a concentration-dependent manner. PRRT2/t-SNARE ratios of 1:1 (red), 2:1 (green), and 3:1 (magenta) are shown. Excess soluble VAMP2 (black) was used as a negative control.(B) Consistent with the polarized assembly of the SNARE proteins, a similar level of inhibition was observed for different PRRT2/t-SNARE ratios (same color scheme as in A) for the labels introduced in the C terminus (SNAP25 residue 193 and VAMP2 residue 75). Averages and SDs from four independent experiments are shown.(C and D) PRRT2 contains a large, intracellular N-terminal proline-rich domain (orange), followed by a membrane associated region (light purple) and a trans-membrane domain (dark purple), connected by a short, flexible loop (green) (C). *In situ* removal of the PRRT2 N-terminal domain using an engineered TEV protease site (denoted by the arrow) (PRRT2^TEV^) as confirmed by SDS-PAGE analysis results in complete loss of PRRT2 function in the lipid-mixing fusion assay (D), indicating that the proline-rich region is the effector domain. The fusion curves for PRRT2 and PRRT2^TEV^ with (open) or without (filled) TEV protease treatment are shown. Representative fusion curves and average values and SDs from three or four independent experiments are shown.

The topological analysis of PRRT2 shows that PRRT2 is a type II transmembrane protein with a C-terminal single membrane-spanning segment and an N-terminal proline-rich domain that localizes intracellularly ([@bib30]). So, we reasoned that the N-terminal proline-rich region, which is ideally positioned to interact with the SNAREs on the pre-synaptic membranes, might be the effector domain. This is reinforced by the low-affinity SNARE interaction, a characteristic of polyproline stretches ([@bib12], [@bib48]). To confirm this, we introduced a tobacco etch virus (TEV) protease cleavage site at residue 248 (PRRT2^TEV^) to allow precise *in situ* excision of the N-terminal domain from the membrane anchor ([Figure 4](#fig4){ref-type="fig"}C). Reconstituted assay showed the PRRT2^TEV^ blocks fusion effectively prior to the TEV treatment, but this inhibition is completely abrogated following the TEV protease cleavage ([Figures 4](#fig4){ref-type="fig"}C and 4D). A control experiment showed that TEV treatment alone does not result in loss of SNARE inhibitory function ([Figure 4](#fig4){ref-type="fig"}D). Thus, not only is the N-terminal region required for clamping, but its close positioning on the membrane is essential for its function. Supporting this, the soluble N-terminal proline-rich domain (residues 1--217) and the reconstituted C-terminal portion (residues 209--341) by themselves are unable to produce the clamping effect ([Figures S4](#mmc1){ref-type="supplementary-material"}C and S4D). Thus, PRRT2 inhibitory activity is achieved by interaction of N-terminal proline-rich domain with the individual SNARE proteins, and its proper positioning on the membrane is also crucial for its function.

Paroxysmal Dyskinesia-Associated *PRRT2* Mutations Disrupt the SNARE-Modulatory Function {#sec2.6}
----------------------------------------------------------------------------------------

Given that PRRT2 negatively regulates synaptic fusion, it is easy to imagine how haploinsufficiency and loss-of-function mutations, which can result in unregulated neurotransmitter release, might ultimately lead to paroxysmal neurological disorders. To test this proposition, we focused on a series of *PRRT2* mutations recently identified in a large cohort of 145 families or patients affected with PKD or other paroxysmal neurological disorders ([@bib8]). In this study, the consequence of the pathogenic mutations in *PRRT2* were evaluated on both protein and mRNA levels. Also, possible non-sense-mediated decay associated with the (truncating and missense) variants was tested with cDNA sequencing and quantification ([@bib8]). A majority of the identified PKD mutations resulted in non-sense-mediated decay; thus, pathogenesis could result from diminished protein levels ([Figure 5](#fig5){ref-type="fig"}A). However, two mutations (p.G305W and p.X341L) did not affect the mRNA levels, implying that these mutations primarily alter the protein function ([Figure 5](#fig5){ref-type="fig"}A). We therefore used our reconstituted fusion assay to investigate the effect of these point mutations on PRRT2 regulatory function. Both the mutations, reconstituted at the same density as the wild-type ([Figure S5](#mmc1){ref-type="supplementary-material"}A), disrupted the PRRT2 clamping ability but to varying degrees ([Figure 5](#fig5){ref-type="fig"}B). The G305W mutation completely abrogated the PRRT2 inhibition, while the X341L (a stop-loss mutation that extends the protein by 27 residues) showed partial loss of function ([Figure 5](#fig5){ref-type="fig"}B). As a control, we looked at a non-pathogenic PRRT2 variant (p.P216H), which was found in a British control population ([@bib8]). The P216H mutation did not alter PRRT2's ability to block SNARE-mediated fusion, underscoring the specificity of the loss-of-function phenotype observed in the PKD-associated p.G305W and p.X341L mutations ([Figure 5](#fig5){ref-type="fig"}B).Figure 5PKD-Associated Mutations in PRRT2 Disrupt Its SNARE-Modulatory Function(A) List of PKD-associated mutations in PRRT2 identified by [@bib8]. The key mutations (highlighted in red) that did not affect the protein levels and exhibit no non-sense-mediated mRNA decay were tested in this study.(B) Lipid-mixing assay showing that the PKD mutations G305W (magenta) and X341L (green) disrupt the SNARE-inhibitory function of PRRT2 (red) to different extents. In comparison, the non-pathogenic P216H (yellow) mutation has no effect on PRRT2 function. Negative control with soluble cytoplasmic domain of VAMP2 (CDV) added in excess to titrate out the t-SNAREs is also shown. Representative fusion curves are shown.(C) Dose analysis shows that the loss of function of G305W mutation (red) in the reconstituted fusion assay is complete and not reversed at a higher dosage of PRRT2. In contrast, the wild-type (blue) PRRT2 shows a typical dose curve. Averages and SDs for three independent trials are shown.(D) Consistently, the single-vesicle exocytosis assay in PC12 cells shows that the G305W mutation abrogates the SNARE-modulatory function of PRRT2 under physiological conditions. Average values and SDs from a minimum of three independent experiments are shown.(E) Single-vesicle docking analysis showing that the PKD-associated G305W mutation introduced in the same molar ratio as the wild-type in the v-SNARE liposomes ([Figure S5](#mmc1){ref-type="supplementary-material"}A) does not impede the SNARE-dependent docking/priming of vesicles to the supported bilayers. Average values and SEMs of three to five independent experiments are shown.(F) FRET-based SNARE assembly assay reveals that the loss of function phenotype results from the inability of G305W mutant (red) to inhibit the SNARE engagement, in contrast to the wild-type (blue) PRRT2. Average values and SDs from three or four independent experiments are shown.

It is noteworthy that the severity of the PKD phenotype observed in the mutations corresponded to the magnitude of its effect in the *in vitro* functional analysis. The X341L variant, which presents partial loss of function, was identified in a patient showing typical PKD episodes with short-lasting dyskinesia triggered by sudden movements or exercise. On the other hand, the G305W missense variant, which resulted in complete loss of function, occurred as a *de novo* mutation in a patient with a severe PKD phenotype. This patient has had presented episodes of PKD, usually triggered by excitement or exercise, since the age of 9 years. Interestingly, her presentation and disease course was remarkably more severe compared with other *PRRT2* mutation carriers, with only partial response to carbamazepine and mild cognitive dysfunction with verbal, memory, and executive function deficits.

Thus, we characterized the G305W mutation in further detail. Dose response using bulk fusion analysis showed that the G305W mutation results in complete loss of function and cannot be rescued by increasing PRRT2 dosage ([Figures 5](#fig5){ref-type="fig"}C and [S5](#mmc1){ref-type="supplementary-material"}A). Consistent with this, the mutated PRRT2 also exhibited reduced efficacy in blocking Ca^2+^-triggered exocytosis in PC12 cells ([Figures 5](#fig5){ref-type="fig"}D and [S5](#mmc1){ref-type="supplementary-material"}B), without an effect on the number of PM-adjacent vesicles ([Figure S5](#mmc1){ref-type="supplementary-material"}B). The single-vesicle docking analysis also confirmed the loss of PRRT2 function in moderating SNARE-mediated priming with the G305W mutation ([Figure 5](#fig5){ref-type="fig"}E). As expected, FRET analysis showed that the G305W mutation eliminates PRRT2 ability to bind and hinder the SNARE complex assembly, and this deficiency is irreversible ([Figures 5](#fig5){ref-type="fig"}F and [S5](#mmc1){ref-type="supplementary-material"}C). Taken together, these data strongly suggest that the pathology of these PKD-associated PRRT2 mutations is directly linked to reduction or loss of its SNARE-regulating function.

Discussion {#sec3}
==========

The data presented here establish that PRRT2 negatively regulates synaptic fusion by directly interfering with the assembly of the SNARE complex. Specifically, it moderates the initial engagement of the cognate SNARE proteins. By doing so, PRRT2 acts to regulate the vesicle priming process, which involves the formation and maintenance of the *trans* SNARE complex, thereby limiting the density of fusion-competent vesicles. This is consistent with the common phenotype observed in all PRRT2 knockdown/KO studies: an accumulation (∼2-fold increase) of vesicles at shorter distances to the PM under resting conditions ([@bib39], [@bib42]) and accelerated replenishment of the readily releasable pool, leading to a higher level of synaptic facilitation ([@bib26], [@bib39]).

Purified PRRT2 binds Syt1 with affinity comparable with the SNAREs, but inclusion of Syt1 or Ca^2+^ does not alter PRRT2 inhibitory function in the reconstituted fusion or SNARE assembly analysis. This, taken together with the fact that PRRT2 moderates Ca^2+^-regulated exocytosis in PC12 cells and has only a modest effect on the efficiency and rate of fusion of pre-docked vesicles, argues against any proposed role for PRRT2 in Ca^2+^ coupling or directly modulating the late stages of vesicle fusion process. PRRT2's role in regulating neurotransmission is still under debate given the conflicting results of the recent *in vivo* studies. Complete loss of PRRT2 either via KO ([@bib26]) or using a truncation (stop codon) mutation ([@bib39]) exhibits no defect in spontaneous or evoked neurotransmitter release. However, short hairpin RNA (shRNA)-based silencing of PRRT2 knocks down both spontaneous and evoked synchronous release and alters the synchronous/asynchronous release ratio ([@bib42]). Some of this variability could be due to the extensive defects in synaptic structure and organization induced by PRRT2 downregulation ([@bib42], [@bib43]). This could be a consequence of the impaired vesicle trafficking process or hints at yet undefined ancillary PRRT2 role in synaptic development and remodeling. Delineating between these possibilities requires further analysis using more subtle alterations in PRRT2, likely involving *de novo* or engineered mutations.

The data also reveal that PKD-associated mutations disrupt the PRRT2 ability to hinder SNARE assembly and block the resultant membrane fusion. The loss of SNARE-moderating function of PRRT2, which likely dysregulates neurotransmitter release resulting in hyper-excitability, provides a simple and straightforward explanation for the episodic neurological phenotypes presented by the PKD mutation carriers. In fact, this might represent a common mechanism underlying the paroxysmal disturbances associated with loss-of-function PRRT2 mutations. PRRT2 mutations often exhibit pleiotropic effects, with identical mutations showing variable phenotypes and presenting different diseases. This suggests that other factors, including genetic makeup, influence the expression of the disease. Nonetheless, the strong correlation between the presentation and severity of PKD phenotype and the loss of SNARE-modulatory function of PRRT2 highlights the physiological relevancy and the critical nature of this ascribed function.

PRRT2 exerts the fusion block via direct interaction of the N-terminal proline-rich domain with the SNARE proteins. Typically, proline-rich regions mediate multi-valent binding but with weak affinity, as these complexes are not structurally well defined ([@bib12], [@bib48]). In this instance, it appears that the weak interaction of proline-rich region with individual SNARE proteins introduces steric hindrance that impedes productive SNARE assembly. Despite the rather weak affinity measured under soluble conditions, PRRT2 reconstituted alongside either the v- or t-SNARE effectively blocks SNARE assembly and function. It is likely that topological restrictions and orientation imposed by membrane anchoring, combined with the increased local concentration, makes PRRT2 more potent under these conditions. Although the exact concentration of PRRT2 at the synapse is not known, it is widely expressed, and its interaction with the fusion machinery has been verified under *in vivo* conditions ([@bib18], [@bib39], [@bib42]). Noteworthy, the weak affinity for assembling SNAREpins might represent a design feature that PRRT2 shares with other synaptic regulators, including Munc13, Munc18, and synaptotagmin, which allows a facile and overlapping control of SNARE complex assembly within the complex and crowded environment of the active zone.

Interestingly, the PKD mutations that were found to cause a severe loss of PRRT2 function (G305W and X341L) without causing non-sense-mediated decay, localize to the C-terminal portion of the protein despite deletion analysis showing that the N-terminal proline-rich region is the primary effector domain. This implies that the C-terminal region also plays a vital role in actuating the SNARE block. It is conceivable that this membrane-proximal, highly conserved amphipathic region interacts with the membranes and/or the SNAREs to position and orient the N terminus to effectively block the initial engagement of the SNARE proteins. This is consistent with our observation that the N-terminal region or C-terminal portion alone is not able to recapitulate a SNARE block. This also highlights the crucial nature of the relative topological configuration of PRRT2 in accomplishing its SNARE-moderating function.

There is limited information on the exact localization of the endogenous PRRT2. Subcellular fractionation analysis shows that PRRT2 is associated with the pre-synaptic area but is diffusely distributed ([@bib39], [@bib42], [@bib43]). The presently identified PRRT2 role in regulating vesicle docking and the aberrant neurotransmission observed under knockdown or KO conditions ([@bib26], [@bib42]) hints at a central role within the active zone. Furthermore, PRRT2 has been shown to bind intersectin1, a scaffold protein involved in the endocytic pathway and concentrated in the periactive zone ([@bib30], [@bib43]). Further research is needed to identify the precise site(s) of PRRT2 action.

In summary, we have uncovered a crucial role of PRRT2 as a regulator of the synaptic SNARE-mediated release of neurotransmitters at the synapse. Mutations in *PRRT2*, either resulting in changes of the gene reading frame (causing non-sense-mediated decay) or affecting active sites involved in regulating SNARE complex assembly, cause protein loss of function and impaired neurotransmission. These results shed new light in the molecular etiology of paroxysmal neurological disorders associated with abnormal pre-synaptic vesicle exocytosis.

Experimental Procedures {#sec4}
=======================

Materials {#sec4.1}
---------

The human PRRT2 gene and mutants were cloned into pGEX6p-1 (GE Healthcare) using restriction sites BamHI and XhoI. SNARE and synaptotagmin constructs used in the fusion assays have been described previously ([@bib23], [@bib25], [@bib46]). For the PC12 cell-based assay, PRRT2 WT and G305W mutant were cloned into pEF1α-HA (Clontech) using restriction enzymes NcoI and EcoRI. The VAMP2-pHluorin construct has been described previously ([@bib27]). Lipids, 1-palmitoyl-2-oleoyl-snglycero-3-phosphocholine (POPC), 1,2-dioleoyl-sn-glycero-3- (phospho-L-serine) (DOPS), 1,2-dipalmitoyl-snglycero-3-phosphoethanolamine-N-(lissamine rhodamine B sulfonyl) (RHO-DOPE), 1,2-dipalmitoyl-sn-glycero-3-phosphoethanolamine-N-(7-nitro-2-1,3-benzoxadiazol-4-yl) (NBD-DOPE), and ATTO647-DOPE were purchased from Avanti Polar Lipids.

Protein Purification {#sec4.2}
--------------------

Synaptotagmin I and all SNARE proteins were expressed and purified as previously described ([@bib25], [@bib41], [@bib46]). The GST-PRRT2 was purified similarly with small modifications. PRRT2 was expressed in *E. coli* strain Rosetta2(DE3) (Novagen), and cells were lysed by cell disruptor (Avestin) in buffer containing 25 mM HEPES (pH 7.4), 400 mM KCl, 4% Triton X-100, 10% glycerol, 0.5 mM Tris(2-carboxyethyl)phosphine hydrochloride (TCEP), and 1 mM phenylmethylsulfonyl fluoride (PMSF). Samples were clarified using a 45Ti rotor (Beckman Coulter) at 140,000 × *g* for 30 min and incubated with glutathione agarose (Pierce) overnight at 4°C. Resin was washed in the same buffer with 1% octylglucoside (OG) and the protein cleaved off the resin using 100 U of PreScission Protease (GE Healthcare) overnight at 4°C. The concentration was determined using a Bradford Assay (BioRad) with BSA as a standard. Protein purity was verified using SDS-PAGE analysis, with Coomassie stain, and identity was confirmed by western blot using a PRRT2 antibody (Atlas). Both showed a single band at ∼60 kDa, corresponding to native protein in the P2 synaptosomal fraction.

Proteoliposome Reconstitution and Bulk Fusion Assay {#sec4.3}
---------------------------------------------------

Proteoliposomes containing SNAREs with or without PRRT2 were prepared using rapid detergent (1% octylglucoside) dilution and dialysis, followed by float-up using a discontinuous Nycodenz gradient as previously described ([@bib10], [@bib46]). The lipid composition was 85% POPC, 15% DOPS, and the final protein/lipid ratio was 1:200 for VAMP2, 1:400 for t-SNARE, and 1:800 for synaptotamin1. PRRT2 was included into the v- or t-SNARE liposome sample as indicated at the desired ratio during reconstitution. The assembled proteoliposomes were diluted, and vitrified samples were analyzed by cryoelectron microscopy for their appearance and quality. The reconstitution efficiency for both SNAREs and PRRT2 were nearly identical (50%--60%), and thus input ratios are denoted in all dose-dependence analysis. A high input concentration of PRRT2 (more than two copies per SNARE) lowered the SNARE reconstitution efficiency, and thus, in order to attain higher ratios, PRRT2 reconstituted into both v- and t-liposomes was used. Liposome fusion assays were performed as previously described at 37°C using a SpectraMax M5 (Molecular Devices) plate reader, and the fluorescence signal was normalized using maximum fluorescence observed after addition of detergent (2.5% \[w/v\] n-dodecylmaltoside \[DM\]).

Single-Vesicle Fusion Analysis {#sec4.4}
------------------------------

Single-vesicle fusion measurements were performed on a free-standing lipid bilayer as described previously ([@bib15]) with some recently described hardware and software modifications (S.K.R., A. Gohlke, F. Li, J.C., X. Wu, J.E.R., and F. Pincet, unpublished data). Briefly, free-standing lipid bilayers were formed from t-SNARE-containing giant unilamellar vesicles (GUVs) prepared using the osmotic shock protocol described recently ([@bib28]). Typically, ∼100 nM (total lipid concentration) of VAMP2-containing vesicles (1:400 protein/lipid ratio, ±PRRT2 at 1:2 molar ratio and 2% ATTO647N-DOPE) were introduced into the chamber, and a laser scanning confocal microscope equipped with a 488 nm argon laser and a 647 nm diode laser was used to track the association and fusion of individual vesicles. All experiments were performed at 37°C, and images were acquired at a speed of 68 ms. The images were then analyzed using custom-made software (S.K.R., A. Gohlke, F. Li, J.C., X. Wu, J.E.R., and F. Pincet, unpublished data) to automatically detect and classify the stages of vesicle docking/undocking and fusion. To measure the overall fusion levels in an unbiased manner ([Figure 1](#fig1){ref-type="fig"}), all vesicles irrespective of tethering/docking status were considered. To explicitly focus on the late stage of membrane fusion ([Figure 3](#fig3){ref-type="fig"}), only vesicles that were firmly docked on the membrane without any detachment in the image sequences before fusion were chosen for the analysis. The PRRT2/t-SNARE ratio is not discernable under these conditions, as the t-SNAREs can freely diffuse on the planar bilayer.

Live Cell Imaging {#sec4.5}
-----------------

PC12 cells were incubated at 37°C in 5% CO~2~ in RPMI 1640, supplemented with 10% horse serum, 5% FBS, MEM non-essential amino acid, 1 mM sodium pyruvate, and 100 μg/mL penicillin/streptomycin (GIBCO). Cells were transferred to Optimem (GIBCO) with 5 μg of Vamp2-pHluorin plasmid DNA and 10 μg of pEF1α-HA, HA-PRRT2, or HA-PRRT2-G305W and then transfected using a NEPA21 Electro-Kinetic electroporator. The transfection and protein expression were verified by western blot analysis using a PRRT2 antibody. For imaging analysis, cells were plated on collagen-4-coated 50 mm glass-bottomed dishes (Mattek) and imaged 48 hr later. Medium was replaced with Live Cell Imaging Solution (GIBCO), and cells were imaged at 37°C using a custom-made TIRF microscope ([@bib29], [@bib49]) using an Olympus IX-70 inverted microscope fitted with a 60×, 1.45 numerical aperture (N.A.). TIRF microscopic lens (Olympus) and controlled by μManager (<https://micro-manager.org>). Excitation of pHluorin was done by the 488 nm line of an Innova 70C-Spectrum ion laser (Coherent). Cells were imaged at 6.6 Hz with 150 ms exposure and detected with a Zyla 4.2 megapixel Camera (Andor Technologies). The emission is collected through a BrightLine full-multiband laser filter set, optimized for 405, 488, 561, and 635 nm laser sources (part number LF405/488/561/635-A-000; Semrock). Single-vesicle exocytosis events were automatically detected using MATLAB software (The MathWorks) described previously ([@bib32], [@bib40], [@bib49]). The statistical significance of the fusion results was established using a Wilcoxon-Mann-Whitney test to account for the non-normal distribution of the data using the open-source software Gnumeric (<http://www.gnumeric.org>).

EM Analysis {#sec4.6}
-----------

Cultured PC12 cells on coverslips were fixed in 2.5% glutaraldehyde in 0.1 M sodium cacodylate buffer (pH 7.4) at room temperature (RT) for 1 hr. The cells were post-fixed in 0.5% osmium tetraoxide (OsO~4~) at RT for 30 min, followed by another 30 min in 1% tannic acid solution. Specimens were stained en bloc with 2% aqueous uranyl acetate for 15 min, dehydrated in a graded series of ethanol to 100%, and embedded in Polybed 812 resin. Blocks were polymerized in a 60°C oven for 24 hr. Thin sections (60 nm) were cut by a Leica ultramicrotome and post-stained with 2% uranyl acetate and lead citrate. Cell sections were examined with a FEI Tecnai transmission electron microscope at 80 kV accelerating voltage; digital images were recorded with an Olympus Morada charge-coupled device (CCD) camera and iTEM imaging software. Images were analyzed using ImageJ to measure the distance between the PM and the dense core vesicles.

Single-Vesicle Docking Analysis {#sec4.7}
-------------------------------

Single-vesicle docking experiments were carried out on supported lipid bilayers as described previously ([@bib11], [@bib50]) with slight modifications. Supported bilayers were prepared by incubating t-SNARE liposomes (∼60 μL of 2 mM total lipid) with 5 mM MgCl~2~ on an Ibidi glass-bottom channel μ-slide for 40 min. The homogeneity and the fluidity of every prepared supported lipid bilayer, after extensive wash with Mg^2+^-free buffer, was verified using NBD-DOPE fluorescence and by fluorescence recovery after photo-bleaching (FRAP), respectively ([Figure S3](#mmc1){ref-type="supplementary-material"}). For docking analysis, ∼100 nM of v-SUVs prepared with VAMP2-4X (VAMP2 with L70D, A74R, A81D, and L84D) and ATT0-647-DPPE ± PRRT2 were allowed to dock on the membranes for 10 min and then extensively washed (20 chamber volume) to remove non-specifically bound SUVs. Approximately 10--12 pictures were collected at different locations of the chip with an inverted Nikon Ti-E total internal reflection (TIRF) microscope equipped with 63X TIRF oil immersion objective (N.A. = 1.45), 647 nm diode laser, and Andor iXon electron-multiplying CCD (EMCCD) camera controlled by NIS-Elements software. Images were projected onto the CCD chip at a magnification of 0.17 μm/pixel with 1.5× intermediate magnification. For an unbiased particle count, we used a custom-written algorithm to count particles from top left to bottom right that ensures every spot is counted only once. The PRRT2/t-SNARE ratio is not discernable under these conditions.

FRET Assay {#sec4.8}
----------

For site-specific labeling with fluorophores, cysteines were introduced into t-SNAREs (SNAP25 residues 20 and 193) and VAMP2 (residues 28 and 75) using the Quickchange (Stratagene) Mutagenesis kit. Thiol-reactive fluorescent probes Oregon green 488 maleimide and Texas red C5 bromoacetamide (Life Technologies) were used to label SNAP25 and VAMP2, respectively, as described previously ([@bib14]). We ensured that the labeling efficiency was \>75% in all cases, and the labeled SNARE proteins and unlabeled PRRT2 were reconstituted into liposomes, and the SNARE assembly was followed as described previously ([@bib14]) using 2.5 μM each of the labeled proteins.

TEV Protease Cleavage Site {#sec4.9}
--------------------------

Site-directed mutagenesis was used to engineer a TEV protease cleavage site in PRRT2 by adding a six-residue recognition sequence (ENLYFQ) at residue 248. PRRT2^TEV^ protein was purified and reconstituted into lipids as described above. The reconstituted liposomes were pre-treated with TEV protease for 2 hr at RT prior to the start of the fusion assays. SDS-PAGE analysis of both free and liposome-reconstituted protein showed that 2 hr at RT results in near complete cleavage.
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